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Abstract
Background: Ethiopia lies in the high-risk corridor of esophageal squamous cell carcinoma in East Africa, where
individuals with this malignancy often do not report established risk factors, suggesting unidentified etiologies.
Here, we report the prevalence of mucosal human papillomavirus (HPV) and of Helicobacter pylori (H. pylori)
detection in endoscopy-obtained esophageal and gastroesophageal junction biopsies and in oral cell specimens
taken at the time of esophageal cancer diagnosis in a case–control study in Addis Ababa, Ethiopia.
Methods: DNA extraction was performed from fresh frozen tissue and oral cell pellets obtained with saline solution
gargling subsequently fixed with ethanol. Mucosal HPV and H. pylori DNA was detected using highly sensitive
assays that combine multiplex polymerase chain reaction and bead-based Luminex technology. The proportions of
specimens testing positive were expressed as percentages, with binomial 95% confidence intervals. Agreement of
results between tissue biopsy and oral cell specimens was estimated using the kappa statistic. Comparison of study
participants’ characteristics by test results was done using the Pearson chi-square test.
Results: HPV DNA was detected in 1 of 62 tumor specimens (2, 95% confidence interval (CI): 0–9%), corresponding
to HPV16 type. HPV DNA was detected in the oral cavity of 7 cases (11, 95% CI: 5–22%) and 4 of 56 matched
healthy controls (7, 95% CI: 2–17%), with multiple HPV types detected. Detection of H. pylori DNA was 55% (95% CI:
42–68%), and 20 of 34 H. pylori-positive specimens (59, 95% CI: 41–75%) were positive for the cagA gene.
Agreement of detection rates between tissue and oral cells in cases was poor for HPV and for H. pylori.
Conclusions: The prevalence of mucosal-type HPV was very low, whereas H. pylori was more commonly detected,
with a high proportion testing positive for the pro-inflammatory gene cagA. These novel findings remain to be
replicated in larger studies and with the addition of serological determinations to better understand their biological
significance in the context of esophageal and gastroesophageal junction cancers.
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Background
Ethiopia forms part of the East Africa high-risk corridor
for esophageal squamous cell carcinoma (ESCC) [1].
Whereas established risk factors for ESCC, such as
tobacco use and alcohol consumption, are considered to
play a role in the etiology of this malignancy in the East
Africa high-risk corridor, several locally suspected risk
factors are thought to be etiologically relevant but are
understudied [2]. A pilot case–control study to explore
the association between qat (or khat) chewing and risk
of esophageal cancer (EC) was recently performed in
Ethiopia. The study suggested an increased risk of EC in
qat consumers among non-tobacco users. In that study,
tobacco use, alcohol consumption, low intake of green
vegetables, illiteracy, and religion were associated with
risk of EC [3]. Infectious agents known to be associated
with other cancer types locally (i.e., human papillomavi-
rus [HPV] and Helicobacter pylori [H. pylori]) could also
contribute etiologically to the occurrence of EC, and
biological specimens were therefore collected to explore
this possible link.
A subgroup of HPV types referred to as high-risk
(HR) HPV types have been identified as the etiological
agents of anogenital cancers and a subset of head and
neck cancers; HPV16 is the most oncogenic type [4]. HR
HPV types encode for two oncoproteins, E6 and E7, that
play a key role in carcinogenesis by interacting with cel-
lular proteins (e.g., p53, pRb, PI3K, Notch) involved in
the cell cycle, apoptosis, and differentiation (reviewed in
[5]). Expression of the two viral proteins is essential to
maintain the transformed phenotype of HPV-infected
cells. The IARC Monographs Working Groups also clas-
sified H. pylori as carcinogenic to humans (IARC Group
1) in patients with chronic infection [4, 6]. H. pylori is
involved in up to 89% of non-cardia gastric cancer cases
worldwide [7], and a link has been established between
chronic H. pylori infection and gastric lymphoma of mu-
cosa-associated lymphoid tissue (MALT lymphoma) [4,
8]. H. pylori strains can be subdivided based on the pres-
ence or absence of a gene that encodes for the cyto-
toxin-associated gene A (CagA) protein: cagA-positive
and cagA-negative strains, respectively. It is well estab-
lished that cagA-positive strains are associated with an
increased risk of developing gastric cancer [9–14]. The
carcinogenic activity of H. pylori is linked to its ability to
deliver the pathogenicity factor CagA protein into the
host gastric epithelial cells [15], where it interferes with
different signaling pathways (e.g., ERK/MAPK, PAR1/
MARK, NF-kappaB, c-Met-PI3K/Akt-mTOR), thus play-
ing a key role in gastric carcinogenesis by inducing se-
cretion of pro-inflammatory cytokines, inhibiting
apoptosis, and promoting cellular proliferation [16–21].
Based on evidence available up to 2009, the IARC
Monographs Working Group concluded that the
epidemiological evidence was inadequate to support a
role for HPV infection in EC etiology, recognizing the
very large geographical variation in the rate of HPV
infection detected in cancer cases [4]. A more recent re-
view within the context of the Tumor Seminar Series co-
ordinated by IARC and the US National Cancer Institute
reported that recent studies suggest that HPV plays little
role in ESCC etiology [22]. Similarly, serology-based
studies of H. pylori infection and risk of ESCC are not
consistent in indicating an association, or its direction
[23–26]. In contrast, there is some evidence that H.
pylori infection is associated with decreased risk of
adenocarcinoma of the esophagus [4].
In Ethiopia, the prevalence of HPV and H. pylori infec-
tions in the upper aerodigestive tract (UADT), including
the esophagus, is unknown in the general population as
well as in patients with UADT cancer undergoing upper
endoscopy. Therefore, the main objective of this study is
to report the prevalence of HPV and of H. pylori detec-
tion in endoscopy-obtained esophageal and gastroesoph-
ageal junction biopsy specimens and in buccal cells
taken at the time of EC diagnosis, in participants in a
case–control study undertaken to inform the planning
of a large-scale etiological study of UADT cancers in
Ethiopia [3].
Methods
Study design and participants
The biological specimens tested in this study were collected
in a hospital-based case–control study conducted in Addis
Ababa, Ethiopia (May 2012–May 2013), considered to be a
pilot study because it was a first study, but with complete
case–control methodology as previously described [3].
Cases of EC and gastroesophageal junction cancer were en-
rolled at two private endoscopy clinics (Adera Higher Clinic
and Mexico Higher Clinic) and at a tertiary-level public
cancer treatment hospital, Tikur Anbessa Hospital (TAH),
and controls were enrolled at TAH. Cancer cases aged 18
years or older with first primary tumors of the esophagus
or gastroesophageal junction were eligible for inclusion
(WHO ICD-O-3 codes: C15.0, C15.3, C15.4, C15.5, C15.8,
C15.9, and C16.0). Controls included cancer-free patients
with diagnoses not related to qat chewing, tobacco use, or
alcohol consumption from the wards of TAH, and healthy
individuals attending TAH to visit inpatients and not re-
lated by blood to study cases (as a sample of the general
population). Controls were matched to cases based on sex,
age, and zone of residence in the country. A total of 133
controls were enrolled and matched to EC and gastro-
esophageal junction cancer cases (73 cases). Although at
least one healthy control (n = 93) was individually matched
to each cancer case, this was not possible for hospital-based
controls because a reduced number were enrolled (n = 40).
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Details on data collection via questionnaire are described
elsewhere [3].
Informed consent
Eligible study participants provided written consent indi-
cating whether they accepted or declined each of the
study components: completion of a risk-factor question-
naire administered by face-to-face interview, blood
drawing, buccal cell collection by oral gargling and spit-
ting, and in addition, for cancer cases, a biopsy of tumor
tissue obtained at endoscopy. The study protocol and
consent forms were reviewed and approved by the
Institutional Review Boards of Addis Ababa University
in Ethiopia and the Morehouse School of Medicine in
Atlanta, USA, and the IARC Ethics Committee in Lyon,
France.
Collection, processing, and storage of biological
specimens (Ethiopia)
Biopsy specimens
Biopsies of suspected tumor tissue at Adera Higher
Clinic and Mexico Higher Clinic were obtained through
endoscopy after sedation. Biopsy tissue punches were
placed in cryotubes and fully immersed in RNA/DNA
Allprotect Tissue Reagent (Qiagen) for fresh tissue pres-
ervation, and initially stored at + 4 °C until transport to
the Armauer Hansen Research Institute (AHRI), for
storage at − 80 °C, on the day of collection, unless the
specimen was collected during a weekend, in which case
it was transported to AHRI on the Monday.
Although this pilot study enrolled 61 EC cases and 12
gastroesophageal junction cancer cases (73 cases), 11 of
these cases were enrolled at TAH, where endoscopy with
biopsy was not performed because these patients had
been diagnosed elsewhere and referred to TAH for can-
cer treatment, with no fresh tissue specimens available.
Therefore, 11 (15%) of the enrolled cancer cases were
excluded from the testing reported here.
Buccal cells
The gargling spit was collected with saline solution, fixed
using 96% ethanol (2:1 ratio), and temporarily stored at
+ 4 °C. At the laboratory, the spit-containing tube was
centrifuged at 3,000 g for 10 min at + 4 °C. The super-
natant was discarded, and the pellet was re-suspended in
1 mL of fixative solution (96% ethanol) with repeated
pipetting and vortexing, and distributed into two
aliquots kept at + 4 °C until shipment to IARC. In the
present investigation, a priori, we opted to test the
buccal cell specimens of only one control for each case,
and among controls, we selected healthy individuals.
Testing of specimens (IARC)
DNA extraction
DNA extraction was performed from frozen tissues and
oral cell pellets using the Qiagen BioRobot EZ1 with the
EZ1 DNA Tissue Kit according to the manufacturer’s in-
structions (Qiagen, Hilden, Germany). Briefly, frozen
tissues and oral cell pellets were incubated in proteinase
K and Buffer G2 (Qiagen, Hilden, Germany) at 56 °C
until the tissue was completely lysed. The DNA was
stored at − 20 °C until further use.
Detection of human papillomavirus and Helicobacter pylori
DNA
The presence of mucosal HPV and H. pylori DNA was
detected using highly sensitive assays that combine
multiplex polymerase chain reaction (PCR) and bead-
based Luminex technology (Luminex Corp., Austin, TX,
USA), as described previously [27–29]. The multiplex
type-specific PCR method uses specific primers for the
detection of 19 probable/possible HR alpha HPV types
(HPV26, 53, 66, 68a and 68b, 70, 73, and 82) or HR
alpha HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59) and 2 low-risk alpha HPV types (HPV6 and
11). Specific primers targeting the 16S rRNA (forward
primer, 5′-TCG CTC ATG GGA TTA GCG AGT ATG-
3′ and reverse primer, 5′-GAA CAT TTC TCT GTA
ATA AAC TGG TT-3′), ureA (forward primer, 5′-GTA
AAT TAG TTC CTG GTG AGT TGT TG-3′ and re-
verse primer, 5′-TTG AAC CGG TCT GTC GCC AAC
AT-3′), and cagA (forward primer 1, 5′-AGC CAC ACA
CGC ATT AAT AGC AAT-3′, forward primer 2, 5′-
AGC CAC ACG CAC TTT AAT AGC AAT-3′, and re-
verse primer, 5′-AAC TTG AAC GAA TCA GAA TAA
TCT TTC-3′) genes from H. pylori were used. Two
primers for the amplification of beta-globin were also
added to provide a positive control for the quality of the
template DNA. The cutoff was calculated as previously
reported by Schmitt et al. [27]. After PCR amplification,
10 μL of each reaction mixture was analyzed using
Luminex technology. For each probe, the median fluor-
escence intensity (MFI) values obtained when no PCR
product was added to the hybridization mixture were
considered as background values. The cutoff was com-
puted by adding 5 MFI to 1.1 × the median background
value, as described by Schmitt et al. [27].
Data analysis
The proportions of specimens testing positive for HPV
DNA (overall and by genotype) or H. pylori (overall, if
either the ureA or the 16S rRNA gene was amplified)
were expressed as percentages with binomial 95% confi-
dence intervals. Among H. pylori-positive specimens, the
proportion testing positive for the virulence gene cagA
was also calculated. Differences in prevalence by type of
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specimen or between cases and controls in oral speci-
mens were determined by the extent of overlap of the
95% confidence intervals around the contrasted propor-
tions (i.e., no overlap meant that the difference was
statistically significant). Agreement of results between
tissue biopsy and oral cell specimens available in cases
was estimated using the kappa statistic. Comparison of
study participants’ characteristics by HPV or H. pylori
test results was done using the Pearson chi-square test.
Results
Included study population
Of 73 enrolled cancer cases, 62 (85%) had tumor tissue
stored for testing. The mean age at diagnosis was 57 ± 12
years, and 29 (47%) of the included samples were from
male patients. Squamous cell carcinoma was the most
common histology (74%), and more malignancies were
detected in the lower third of the esophagus than in other
segments (Table 1). Cases differed from controls in educa-
tion and religion. Cases had higher prevalence of ever
(32% vs. 16%) and current (15% vs. 2%) tobacco use than
controls but lower prevalence of ever (32% vs. 45%) and
current (8% vs. 20%) alcohol consumption (Table 1).
HPV prevalence
Tumor tissue
Fresh frozen tissue specimens were available for testing in
62 cases (100%). All specimens were beta-globin-positive.
HPV DNA was detected in 1 tumor specimen (2, 95% CI:
0–9%; Table 2), corresponding to infection with oncogenic
HPV16 in a case of ESCC with the biopsy taken from the
upper third of the esophagus. All specimens tested
negative for all other mucosal HPV types.
Buccal cells
Buccal cells were available in 61 of 62 cancer cases
(98%). All specimens were beta-globin-positive. HPV
DNA was detected in the oral cavity of 7 cases (11, 95%
CI: 5–22%). HPV31 and HPV56 genotypes were each de-
tected in the buccal cells of 2 cases (3, 95% CI: 0–11%),
and HPV16, HPV18, HPV35, HPV51, and HPV66 geno-
types were detected in 1 case each (Table 2). Specimens
from 2 cases had dual HPV infections, with the follow-
ing combinations of genotypes: HPV31 and HPV35 in 1
case and HPV56 and HPV66 in 1 case. Low-risk HPV
types were not identified in the oral cells of cases. No
HPV DNA was identified in the oral cells of the ESCC
case with HPV16 detected in the tissue biopsy. The con-
cordance of HPV detection between tissue biopsy and
buccal cells in cases was very poor (kappa = − 0.03).
Of 62 healthy matched controls, 57 (92%) had oral
cells available for testing. Of these specimens, one was
beta-globin-negative and was excluded from further con-
sideration. HPV DNA was detected in the oral cavity of
4 of 56 matched healthy controls (7, 95% CI: 2–17%).
The following genotypes were identified in the oral
cavity: HPV16, HPV18, HPV35, HPV39, HPV53, and
HPV66. Specimens from 2 controls had dual detection,
with the following combination of genotypes: HPV18
and HPV39 in 1 control and HPV35 and HPV66 in 1
control. Low-risk HPV types were not identified in the
oral cells of healthy controls. The proportion of controls
with HR HPV DNA-positive buccal cells was similar to
the proportion observed in cases.
Helicobacter pylori
Tumor tissue
All 62 fresh frozen tissue specimens (100%) were beta-
globin-positive. Detection of H. pylori DNA was com-
mon: 55% (95% CI: 42–68%). An equal proportion tested
positive for H. pylori 16S and for H. pylori ureA: 30 of
62, or 48% (95% CI: 35–61%). Of 34 H. pylori-positive
specimens, 20 were positive for the cagA gene (59, 95%
CI: 41–75%) (Table 2). The mean age was 57 ± 12 years
for H. pylori-positive cases and 56 ± 13 years for H.
pylori-negative cases. The comparison of cases by H.
pylori status did not identify demographic or clinical
factors associated with positivity (Table 3). However, the
distribution of cases by H. pylori status differed by
center of enrolment (p = 0.02).
Buccal cells
Among the 61 cases with buccal cells, 8 (13%) had H.
pylori-positive oral specimens (95% CI: 6–24%) (Table 2).
A slightly larger proportion of specimens were positive
by the ureA test (13, 95% CI: 6–24%) than by the 16S
test (5, 95% CI: 1–14%). One quarter of H. pylori-in-
fected oral specimens tested positive for the cagA gene
(Table 2). The concordance of overall H. pylori detection
between tissue biopsy and buccal cells in cases was very
poor (kappa = 0.02).
The prevalence of H. pylori detection in buccal cells of
controls was 7% (95% CI: 2–17%). Of 4 H. pylori-positive
samples, 2 tested positive for the cagA gene (Table 2).
Discussion
The prevalence of HPV DNA in fresh frozen EC and
gastroesophageal junction cancer tissue biopsies in our
study sample was very low (2%), based on 62 specimens,
with only a single biopsy positive for HPV16. Relying on
overall findings or restricting results to those from ESCC
specimens (1 of 46, or 2%), the prevalence of mucosal
HPV detection in esophageal tissue in our study differs
from that in similar testing conducted elsewhere in
Africa. A study in Malawi, the country with the highest
EC incidence in East Africa, reported a HPV16 positivity
of 15% among 40 patients with ESCC undergoing
endoscopy with formalin-fixed, paraffin-embedded tissue
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Table 1 Characteristics of esophageal and gastroesophageal junction cancer cases and matched healthy controls with biospecimens
tested
Esophageal (N = 62) Healthy control (N = 56) Pearson Chi2
p-valueN % N %
Sex
Male 29 47% 28 50% 0.73
Female 33 53% 28 50%
Age at recruitment (years)
< 40 6 10% 6 11% 0.67
40–49 10 16% 11 20%
50–59 18 29% 20 36%
60+ 28 45% 19 34%
Ethnicity
Oromo 31 50% 24 43% 0.39
Amhara 8 13% 15 27%
Gurage 7 11% 5 9%
Somali 6 10% 3 5%
Other 10 16% 9 16%
Region of residence
Oromia 38 61% 32 57% 0.90
South Ethiopia (SNNP) 13 21% 13 23%
Other 11 18% 11 20%
Education
None 14 23% 42 75% < 0.01
Any schooling 48 77% 13 23%
Missing . . 1 2%
Religion
Christian 24 39% 38 68% < 0.01
Other 38 61% 18 32%
Alcohol use
Never alcohol drinker 42 68% 31 55% 0.16
Former alcohol drinker 15 24% 14 25%
Current alcohol drinker 5 8% 11 20%
Tobacco use
Never tobacco user 42 68% 47 84% 0.03
Former tobacco user 11 18% 8 14%
Current tobacco user 9 15% 1 2%
Center of enrolment
Tikur Anbessa Specialized Hospital . . 56 100%
Mexico Higher Clinic 40 65% . .
Adera Higher Clinic 22 35% . .
Location of tumor
. . . 56 100%
Upper third of esophagus 4 6% . .
Middle third of esophagus 19 31% . .
Lower third of esophagus 21 34% . .
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biopsy specimens tested using multiplex quantitative
PCR and in situ hybridization [30]. However, other stud-
ies in East Africa did not reveal evidence of infection
with HPV [31, 32].
The different findings among published studies across
East Africa could reflect true differences in the rate of
HPV infection in tumor specimens and/or differences in
the rate of detection, possibly associated with the
methods used in the selection of patients and the testing
of specimens and the different types and quality of spec-
imens used (formalin-fixed versus fresh tumor tissue,
vulnerability to contamination, number and size of
biopsy punches, little vs. abundant malignant tissue in
biopsies). None of the adenocarcinoma tissue biopsies in
our study tested positive for HPV, in agreement with the
findings of a study in Australia that included both EC
and gastroesophageal junction adenocarcinomas [33].
In our study, the diversity of HPV types seen in the
oral cavity of cases was not informative of the diversity
of HPV types detected further down in the esophagus.
For cancer sites for which HPV is an established causal
agent, the prevalence and agreement of detection across
different types of specimens is larger. For instance,
higher prevalence of HR HPV types and agreement of
HPV detection between tumor tissue (20%) and oral
cells (23%) in US cases of head and neck cancer has pre-
viously been reported [34]. In contrast, a reduced agree-
ment of HPV detection between oral cavity and cervical
or tonsillar biopsies has previously been reported in can-
cer-free adult populations, with oral gargling or rinse
specimens displaying higher prevalence (12.4%) than
tonsil frozen biopsies (2.3%) but lower prevalence than
cervical mucosa (2.4% vs. 29%) [35, 36]. The poor agree-
ment in the rate of detection we observed between EC
tissue and oral cavity cells could be related to the virus
having different rates of clearance in the mucosa of these
anatomical sites. Another consideration is related to the
very small size of the tissue biopsy punch examined,
which may have included a fraction of tissue not
representative of the presumably infected mucosa in the
organ, whereas gargling washes the entire buccal and
pharyngeal zones, collecting a more representative
sample.
The majority of the HPV genotypes detected in the
oral cells of cases and controls have been found to be
present in the cervical cytology of women with normal
and also with abnormal findings in Ethiopia [37–39].
The overall prevalence of HPV detection in oral cells of
controls in our small study (7, 95% CI, 2–17%) agrees
with the previously reported prevalence of oral HPV in-
fection detected in a large study of the US general popu-
lation (6.9, 95% CI: 5.7–8.3%), including similar
prevalence of HPV16 (1%) and overlap with other geno-
types as well [40].
Helicobacter pylori
This is one of the very few studies that documents H.
pylori testing of esophageal and gastroesophageal junc-
tion tumor tissue specimens as opposed to gastric tissue.
Detection of H. pylori was rather common in the Ethiop-
ian biopsy specimens: 55% (95% CI: 42–68%). H. pylori
is commonly found in the superficial mucosal layer of
the stomach [4] and can be found in the esophagus. Be-
cause in our study a large proportion of biopsies were col-
lected from the lower part of the esophagus, closer to the
gastroesophageal junction, the anatomical proximity to
cardia tissue may explain the presence of H. pylori, per-
haps as a superficial contaminant of the esophageal biop-
sies originating from the stomach. H. pylori infection has
been commonly detected in patients undergoing endos-
copy for gastrointestinal problems in Ethiopia and in other
African countries, and also in symptomatic patients
screened using stool specimens [41–44].
The IARC in-house CagA-based PCR assay determined
that more than half of the H. pylori-positive specimens
tested positive (59%) for the cagA gene. The presence of
this gene is considered to be associated with H. pylori
virulence and contributes to neoplastic transformation in
Table 1 Characteristics of esophageal and gastroesophageal junction cancer cases and matched healthy controls with biospecimens
tested (Continued)
Esophageal (N = 62) Healthy control (N = 56) Pearson Chi2
p-valueN % N %
Esophagus, unspecified 7 11% . .
Junction 11 18% . .
Histology
. . . 56 100%
Squamous cell carcinoma 46 74% . .
Adenocarcinoma 11 18% . .
Mixed 3 5% . .
Other 2 3% . .
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the gastric mucosa [21, 45, 46]; however, further studies
are required to complement these data by determining the
CagA antibody levels in serum, and to assess its role, if
any, in the development of EC and gastroesophageal junc-
tion cancers. To our knowledge, this study is the first to
test for the cagA gene in EC and gastroesophageal junc-
tion cancer biopsies in the East Africa EC high-risk
corridor.
The findings of our study, and their interpretation, are
based on a small number of cancer patients with
reduced sampling of the malignant tissue seen during
endoscopy; these study characteristics may have affected
the reported results. Also, the presence of H. pylori in
EC and gastroesophageal junction cancer cases may be
partly explained by contaminants from the stomach,
thus representing a challenge in the investigation of the
role of H. pylori in EC and a potential weakness of the
present study. Further studies are required to determine
whether H. pylori plays a direct role in esophageal
carcinogenesis.
Conclusions
The prevalence of mucosal-type HPV was very low in
EC biopsies collected in cancer cases enrolled in a study
in Addis Ababa. Single infection with HR HPV16 was
detected in the tissue specimen of 1 case (2%), and 7 HR
HPV types were identified in the oral cells of 7 cases
(11%), including multiple types detected in 2 cases. The
prevalence of HPV in oral cells was similar in cases and
controls, with considerable overlap of types. In contrast,
the prevalence of H. pylori detected in EC biopsies was
much higher (55%), with a high proportion containing
the pro-inflammatory gene cagA.
Abbreviations
cagA: Cytotoxin-associated gene A; CI: Confidence interval; c-Met-PI3K/Akt-
mTOR: c-Met-phosphatidylinositol 3-kinase / Akt-mammalian target of
Table 3 Characteristics of esophageal and gastroesophageal junction cancer cases grouped by fresh frozen endoscopy biopsy H.
pylori status
Esophageal (N = 62) Pearson Chi2
p-valueHp negative (N = 28) Hp positive - cagA negative (N = 14) Hp positive - cagA positive (N = 20)
N % N % N %
Sex
Male 13 46% 5 36% 11 55% 0.54
Female 15 54% 9 64% 9 45%
Age at recruitment (years)
< 40 3 11% . . 3 15% 0.83
40–49 5 18% 3 21% 2 10%
50–59 8 29% 4 29% 6 30%
60+ 12 43% 7 50% 9 45%
Education
None 6 21% 3 21% 5 25% 0.95
Any schooling 22 79% 11 79% 15 75%
Center of enrolment
Mexico Higher Clinic 13 46% 10 71% 17 85% 0.02
Adera Higher Clinic 15 54% 4 29% 3 15%
Location of tumor
Upper third of esophagus 3 11% 1 7% . . 0.76
Middle third of esophagus 7 25% 5 36% 7 35%
Lower third of esophagus 9 32% 6 43% 6 30%
Esophagus, unspecified 4 14% 1 7% 2 10%
Junction 5 18% 1 7% 5 25%
Histology
Squamous cell carcinoma 22 79% 11 79% 13 65% 0.62
Adenocarcinoma 4 14% 2 14% 5 25%
Mixed 1 4% . . 2 10%
Other 1 4% 1 7% . .
Hp = H. pylori
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rapamycin; EC: Esophageal cancer; ERK/MAPK: Extracellular signal-regulated
kinase / mitogen activated protein kinase; ESCC: Esophageal squamous cell
carcinoma; H. pylori: Helicobacter pylori; HPV: Human papillomavirus; HR: High-
risk; IARC: International Agency for Research on Cancer; ICD-O-3: International
classification of diseases for oncology, third edition; MALT: Mucosa-
associated lymphoid tissue; MFI: Median fluorescence intensity; NF-
kappaB: Nuclear factor-kappa B; PAR-1/MARK: Partitioning-defective 1 /
microtubule-affinity regulating kinase; PCR: Polymerase chain reaction;
TAH: Tikur Anbessa Hospital; UADT: Upper aerodigestive tract; WHO: World
Health Organization
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